Short Interest in Forty Seven Inc (NASDAQ:FTSV) Rises By 15.4%

Share on StockTwits

Forty Seven Inc (NASDAQ:FTSV) was the recipient of a large increase in short interest in May. As of May 31st, there was short interest totalling 2,028,200 shares, an increase of 15.4% from the April 30th total of 1,757,500 shares. Based on an average daily trading volume, of 207,800 shares, the days-to-cover ratio is presently 9.8 days. Approximately 15.1% of the company’s shares are short sold.

In other Forty Seven news, Director Irving Weissman sold 10,000 shares of the company’s stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of $15.98, for a total transaction of $159,800.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Chris H. Takimoto sold 8,000 shares of the company’s stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $16.39, for a total value of $131,120.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 118,311 shares of company stock worth $1,998,221. Company insiders own 37.40% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. PNC Financial Services Group Inc. acquired a new stake in Forty Seven during the 1st quarter worth $32,000. BNP Paribas Arbitrage SA acquired a new stake in Forty Seven during the 1st quarter worth $48,000. Essex Investment Management Co. LLC acquired a new stake in Forty Seven during the 4th quarter worth $70,000. Metropolitan Life Insurance Co NY acquired a new stake in Forty Seven during the 1st quarter worth $88,000. Finally, New York State Common Retirement Fund acquired a new stake in Forty Seven during the 4th quarter worth $101,000. 47.34% of the stock is currently owned by institutional investors.

Several research analysts have issued reports on the company. Zacks Investment Research raised Forty Seven from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a report on Wednesday, May 8th. HC Wainwright set a $21.00 price objective on Forty Seven and gave the stock a “buy” rating in a report on Tuesday, May 14th. Roth Capital initiated coverage on Forty Seven in a report on Wednesday, May 29th. They set a “buy” rating and a $28.00 price objective on the stock. Guggenheim initiated coverage on Forty Seven in a research note on Friday, April 12th. They issued a “buy” rating on the stock. Finally, Oppenheimer reissued a “buy” rating on shares of Forty Seven in a research note on Tuesday, March 19th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. Forty Seven currently has an average rating of “Buy” and a consensus target price of $26.89.

Shares of FTSV stock traded up $0.24 during trading hours on Wednesday, reaching $10.73. The company had a trading volume of 200,400 shares, compared to its average volume of 184,153. The company has a market cap of $347.77 million and a P/E ratio of -2.86. Forty Seven has a 1-year low of $9.90 and a 1-year high of $23.83.

Forty Seven (NASDAQ:FTSV) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.14). Analysts predict that Forty Seven will post -2.72 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Short Interest in Forty Seven Inc (NASDAQ:FTSV) Rises By 15.4%” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/4380287/short-interest-in-forty-seven-inc-nasdaqftsv-rises-by-15-4.html.

Forty Seven Company Profile

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.

See Also: What is range trading?

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Outfront Media  Upgraded by Zacks Investment Research to “Hold”
Outfront Media Upgraded by Zacks Investment Research to “Hold”
Orion Engineered Carbons  Downgraded to “Sell” at Zacks Investment Research
Orion Engineered Carbons Downgraded to “Sell” at Zacks Investment Research
Zacks Investment Research Downgrades Norbord  to Sell
Zacks Investment Research Downgrades Norbord to Sell
Norbord’s  “Buy” Rating Reiterated at Raymond James
Norbord’s “Buy” Rating Reiterated at Raymond James
On Deck Capital  Given “Neutral” Rating at BTIG Research
On Deck Capital Given “Neutral” Rating at BTIG Research
OneMain  Upgraded by JPMorgan Chase & Co. to “Overweight”
OneMain Upgraded by JPMorgan Chase & Co. to “Overweight”


© 2006-2019 Ticker Report